CA1269659A
(en)
*
|
1984-08-06 |
1990-05-29 |
Brigham Young University |
Method for the production of 2'-deoxyadenosine compounds
|
CA1295998C
(en)
*
|
1985-07-29 |
1992-02-18 |
Sai P. Sunkara |
Nucleosides and their use as antineoplastic agents
|
US4814438A
(en)
*
|
1986-12-24 |
1989-03-21 |
Eli Lilly And Company |
Immunoglobulin conjugates of 2',2'-difluronucleosides
|
US4994558A
(en)
*
|
1986-12-24 |
1991-02-19 |
Eli Lilly And Company |
Immunoglobulin conjugates
|
PT86377B
(pt)
*
|
1986-12-24 |
1990-11-20 |
Lilly Co Eli |
Processo para a preparacao de conjugados de imunoglobulinas com um difluoronucleosideo acilado
|
US4965374A
(en)
*
|
1987-08-28 |
1990-10-23 |
Eli Lilly And Company |
Process for and intermediates of 2',2'-difluoronucleosides
|
ES2176279T3
(es)
*
|
1987-08-28 |
2002-12-01 |
Lilly Co Eli |
Procedimiento estereoselectivo para preparar 2`-2`-difluorolactonen protegidos.
|
US5223608A
(en)
*
|
1987-08-28 |
1993-06-29 |
Eli Lilly And Company |
Process for and intermediates of 2',2'-difluoronucleosides
|
US4914028A
(en)
*
|
1988-02-10 |
1990-04-03 |
Eli Lilly And Company |
Method of preparing beta-2',2'-difluoronucleosides
|
DE68923387T2
(de)
*
|
1988-02-16 |
1996-01-25 |
Lilly Co Eli |
2',3'-Dideoxy-2',2'-difluornucleoside.
|
US5644043A
(en)
*
|
1988-02-16 |
1997-07-01 |
Eli Lilly And Company |
2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
|
US4996308A
(en)
*
|
1988-03-25 |
1991-02-26 |
Merrell Dow Pharmaceuticals Inc. |
Derivatives with unsaturated substitutions for the 5'-hydroxymethyl group
|
JPH0232093A
(ja)
*
|
1988-06-08 |
1990-02-01 |
Merrell Dow Pharmaceut Inc |
抗レトロウィルスジフルオロ化ヌクレオシド類
|
CA2004695C
(en)
*
|
1988-12-12 |
1999-08-10 |
Rosanne Bonjouklian |
Phospholipid nucleosides
|
AU4134793A
(en)
*
|
1992-06-22 |
1993-12-23 |
Eli Lilly And Company |
2'-deoxy-2',2'-difluoro(2,6,8-substituted) purine nucleosides having anti-viral and anti-cancer activity and intermediates
|
YU43193A
(sh)
*
|
1992-06-22 |
1997-01-08 |
Eli Lilly And Company |
2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
|
AU671491B2
(en)
*
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
US5424416A
(en)
*
|
1993-08-25 |
1995-06-13 |
Eli Lilly And Company |
Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
|
US5480992A
(en)
*
|
1993-09-16 |
1996-01-02 |
Eli Lilly And Company |
Anomeric fluororibosyl amines
|
US5637688A
(en)
*
|
1994-12-13 |
1997-06-10 |
Eli Lilly And Company |
Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
|
US5559222A
(en)
*
|
1995-02-03 |
1996-09-24 |
Eli Lilly And Company |
Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
|
CA2278056C
(en)
*
|
1997-01-24 |
2006-12-12 |
Norsk Hydro Asa |
Gemcitabine derivatives
|
EP0994715A4
(de)
*
|
1997-03-24 |
2001-08-08 |
Lilly Co Eli |
Difluornukleosid-phosphorsäuren und ihre derivate
|
TW466112B
(en)
*
|
1998-04-14 |
2001-12-01 |
Lilly Co Eli |
Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
|
US6326507B1
(en)
*
|
1998-06-19 |
2001-12-04 |
Trustees Of Dartmouth College |
Therapeutic compounds and methods of use
|
US20050281821A1
(en)
*
|
1999-01-06 |
2005-12-22 |
Flavia Pernasetti |
Method and composition for angiogenesis inhibition
|
ES2265948T3
(es)
*
|
1999-06-14 |
2007-03-01 |
Cancer Research Technology Limited |
Terapia para el cancer.
|
JP2004505047A
(ja)
*
|
2000-07-28 |
2004-02-19 |
キャンサー・リサーチ・テクノロジー・リミテッド |
複合治療による癌治療
|
GB0019124D0
(en)
*
|
2000-08-03 |
2000-09-27 |
Pfizer |
Novel process
|
DE60134679D1
(de)
*
|
2000-10-20 |
2008-08-14 |
Eisai R&D Man Co Ltd |
Stickstoff enthaltende aromatische Heterozyklen
|
US6822001B2
(en)
*
|
2000-11-03 |
2004-11-23 |
Tularik Inc. |
Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
|
US20050250854A1
(en)
*
|
2000-11-03 |
2005-11-10 |
Amgen Inc. |
Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
|
US7435755B2
(en)
|
2000-11-28 |
2008-10-14 |
The Trustees Of Dartmouth College |
CDDO-compounds and combination therapies thereof
|
GB0121285D0
(en)
*
|
2001-09-03 |
2001-10-24 |
Cancer Res Ventures Ltd |
Anti-cancer combinations
|
US20030139373A1
(en)
*
|
2001-11-20 |
2003-07-24 |
Breimer Lars Holger |
Method for cancer therapy
|
US7365167B2
(en)
*
|
2001-11-26 |
2008-04-29 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
US7390885B2
(en)
*
|
2001-11-26 |
2008-06-24 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
CA2471509A1
(en)
*
|
2002-01-14 |
2003-07-17 |
Novartis Ag |
Combinations comprising epothilones and anti-metabolites
|
CA2472581C
(en)
*
|
2002-01-15 |
2012-06-26 |
Trustees Of Dartmouth College |
Tricyclic-bis-enone derivatives and methods of use thereof
|
AU2003217402A1
(en)
*
|
2002-02-14 |
2003-09-04 |
Pharmasset Inc |
Modified fluorinated nucleoside analogues
|
GB2386836B
(en)
*
|
2002-03-22 |
2006-07-26 |
Cancer Res Ventures Ltd |
Anti-cancer combinations
|
GB0223380D0
(en)
*
|
2002-10-09 |
2002-11-13 |
Astrazeneca Ab |
Combination therapy
|
GB2394658A
(en)
*
|
2002-11-01 |
2004-05-05 |
Cancer Rec Tech Ltd |
Oral anti-cancer composition
|
EP1604665B1
(de)
*
|
2003-03-10 |
2011-05-11 |
Eisai R&D Management Co., Ltd. |
C-kit kinase-hemmer
|
EP1631258A1
(de)
*
|
2003-05-20 |
2006-03-08 |
Aronex Pharmaceuticals Inc. |
Kombinationschemotherapie mit gemcitabin und einem liposomalen platinkomplex
|
WO2004105747A1
(en)
*
|
2003-05-20 |
2004-12-09 |
Aronex Pharmaceuticals, Inc |
Combination chemotherapy comprising capecitabine and a liposomal platinum complex
|
DE10323279A1
(de)
*
|
2003-05-21 |
2004-12-16 |
Stada Arzneimittel Ag |
Gebrauchsfertige Gemcitabin-Lösungen
|
GB0321999D0
(en)
*
|
2003-09-19 |
2003-10-22 |
Cancer Rec Tech Ltd |
Anti-cancer combinations
|
EP1683785B1
(de)
*
|
2003-11-11 |
2013-10-16 |
Eisai R&D Management Co., Ltd. |
Harnstoffderivate und verfahren zu deren herstellung
|
EP1711188B1
(de)
*
|
2004-02-06 |
2012-06-06 |
Threshold Pharmaceuticals, Inc. |
Krebstherapien
|
AU2005240020B2
(en)
*
|
2004-04-22 |
2011-02-10 |
Eli Lilly And Company |
Composition comprising a Survivin oligonucleotide and gemcitabine for the treatment of cancer
|
ES2322175T3
(es)
*
|
2004-09-17 |
2009-06-17 |
EISAI R&D MANAGEMENT CO., LTD. |
Composicion medicinal con estabilidad mejorada y gelificacion reducida.
|
US20060089328A1
(en)
*
|
2004-10-22 |
2006-04-27 |
Edgar Schridde |
Ready-to-use gemcitabine solutions
|
US20060089329A1
(en)
*
|
2004-10-22 |
2006-04-27 |
Edgar Schridde |
Ready-to-use gemcitabine solution concentrates
|
US7563570B2
(en)
*
|
2004-10-29 |
2009-07-21 |
Pangaea Biotech |
Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
|
CA2586687A1
(en)
*
|
2004-12-08 |
2006-06-15 |
Sicor Inc. |
Difluoronucleosides and process for preparation thereof
|
DE102004063347A1
(de)
*
|
2004-12-23 |
2006-07-13 |
Stada Arzneimittel Ag |
Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
|
MY142304A
(en)
|
2005-01-31 |
2010-11-15 |
Taiho Pharmaceutical Co Ltd |
Novel pyrimidine nucleoside compound or salt thereof
|
ATE458743T1
(de)
*
|
2005-03-04 |
2010-03-15 |
Fresenius Kabi Oncology Ltd |
Zwischenprodukt und verfahren zur herstellung von an beta-anomeren angereicherten 2'-desoxy,2',2'- difluor-d-ribufuranosylnukleosiden
|
US7485716B2
(en)
|
2005-05-02 |
2009-02-03 |
Pharmaessentia Corp. |
Stereoselective synthesis of β-nucleosides
|
WO2007015569A1
(ja)
*
|
2005-08-01 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を予測する方法
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
EP1928497A2
(de)
*
|
2005-08-24 |
2008-06-11 |
Cell-Matrix, Inc. |
Kombinationstherapien zur hemmung von interaktionen zwischen integrin und extrazellulärer matrix
|
JP2009506019A
(ja)
*
|
2005-08-26 |
2009-02-12 |
アンティソーマ・ピーエルシー |
癌治療のための組み合わせ
|
US20090053236A1
(en)
*
|
2005-11-07 |
2009-02-26 |
Eisai R & D Management Co., Ltd. |
USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
|
EP1964837A4
(de)
*
|
2005-11-22 |
2010-12-22 |
Eisai R&D Man Co Ltd |
Antitumormittel gegen multiples myelom
|
WO2007136103A1
(ja)
*
|
2006-05-18 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
甲状腺癌に対する抗腫瘍剤
|
JPWO2008001956A1
(ja)
*
|
2006-06-29 |
2009-12-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
肝線維症治療剤
|
TW200817426A
(en)
|
2006-07-21 |
2008-04-16 |
Taiho Pharmaceutical Co Ltd |
2'-cyanopyrimidine nucleoside compound
|
NZ574362A
(en)
|
2006-07-24 |
2010-10-29 |
Taiho Pharmaceutical Co Ltd |
3'-ethynylcytidine derivative
|
WO2008026748A1
(fr)
*
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
US8921340B2
(en)
|
2006-11-17 |
2014-12-30 |
Trustees Of Dartmouth College |
Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
|
WO2008064133A1
(en)
*
|
2006-11-17 |
2008-05-29 |
Trustees Of Dartmouth College |
Synthesis and biological activities of new tricyclic-bis-enones (tbes)
|
WO2008064132A2
(en)
*
|
2006-11-17 |
2008-05-29 |
Trustees Of Dartmouth College |
Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
|
CA2675736A1
(en)
|
2007-01-19 |
2008-07-24 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of pancreatic cancer
|
KR101445892B1
(ko)
*
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암 치료용 조성물
|
US8765690B2
(en)
*
|
2007-04-05 |
2014-07-01 |
Threshold Pharmaceuticals, Inc. |
Treatment of cancer with glufosfamide in patients not receiving insulin therapy
|
US20090048205A1
(en)
*
|
2007-08-15 |
2009-02-19 |
Colin Meyer |
Combination therapy with synthetic triterpenoids and gemcitabine
|
JO2778B1
(en)
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain vehicles, installations and methods
|
AU2008323923A1
(en)
|
2007-11-06 |
2009-05-14 |
Pharmaessentia Corporation |
Novel synthesis of beta-nucleosides
|
AR069198A1
(es)
|
2007-11-07 |
2010-01-06 |
Schering Corp |
Derivados de ribosil pirimidinas moduladores de quinasas de control chk1,y composiciones farmaceuticas que los comprenden utiles en el tratamiento del cancer.
|
US8952035B2
(en)
|
2007-11-09 |
2015-02-10 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
CN108434151A
(zh)
|
2008-01-11 |
2018-08-24 |
里亚塔医药公司 |
合成三萜类化合物及用以治病之方法
|
MX2010008187A
(es)
*
|
2008-01-29 |
2010-08-10 |
Eisai R&D Man Co Ltd |
Uso combinado de inhibidor de angiogenesis y taxano.
|
MX2010011439A
(es)
|
2008-04-18 |
2011-01-25 |
Reata Pharmaceuticals Inc |
Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
|
US8124799B2
(en)
|
2008-04-18 |
2012-02-28 |
Reata Pharmaceuticals, Inc. |
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
|
WO2009146218A2
(en)
|
2008-04-18 |
2009-12-03 |
Reata Pharmaceuticals, Inc. |
Compounds including an anti-inflammatory pharmacore and methods of use
|
EA022588B1
(ru)
|
2008-04-18 |
2016-01-29 |
Ритэ Фамэсутикл, Инк. |
Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце
|
TW201004627A
(en)
|
2008-04-18 |
2010-02-01 |
Reata Pharmaceuticals Inc |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
EP2859916B1
(de)
|
2008-05-22 |
2017-11-29 |
Galera Labs, LLC |
Antimitotika mit Superoxid Dismutase Mimetika für die Kombinationstherapie gegen Krebs
|
JP5758801B2
(ja)
*
|
2008-07-22 |
2015-08-05 |
トラスティーズ・オブ・ダートマス・カレッジTrustees of Dartmouth College |
単環式シアノエノンおよびその使用方法説明
|
WO2010019396A1
(en)
*
|
2008-08-13 |
2010-02-18 |
Threshold Pharmaceuticals, Inc. |
Administration of glufosfamide for the treatment of cancer
|
EP2416781B1
(de)
*
|
2009-04-06 |
2017-03-08 |
Otsuka Pharmaceutical Co., Ltd. |
Kombination von antineoplastischen arzneimitteln auf cytidin-basis mit cytidin-deaminase-inhibitor und ihre verwendung in der krebstherapie
|
TWI503121B
(zh)
*
|
2009-04-06 |
2015-10-11 |
Otsuka Pharma Co Ltd |
用以治療癌症之組成物及方法
|
AU2010234637B2
(en)
*
|
2009-04-06 |
2016-05-12 |
Otsuka Pharmaceutical Co., Ltd. |
(2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer
|
US8609631B2
(en)
|
2009-04-06 |
2013-12-17 |
Eisai Inc. |
Compositions and methods for treating cancer
|
GB0907551D0
(en)
|
2009-05-01 |
2009-06-10 |
Univ Dundee |
Treatment or prophylaxis of proliferative conditions
|
EP2473041B1
(de)
|
2009-09-04 |
2018-03-07 |
Merck Sharp & Dohme Corp. |
Modulatoren von zellzyklus-kontrollpunkten und ihre verwendung in kombination mit kontrollpunkt-kinasehemmern
|
WO2011101644A1
(en)
|
2010-02-18 |
2011-08-25 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Triazolo [4, 5 - b] pyridin derivatives
|
EP2547359B1
(de)
|
2010-03-15 |
2016-03-09 |
The Board of Trustees of the University of Illionis |
Hemmer von interaktionen, die beta-integrin-g protein-alpha-untereinheit binden
|
WO2011143590A1
(en)
|
2010-05-14 |
2011-11-17 |
Cornerstone Pharmaceuticals, Inc. |
Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
|
WO2011143593A1
(en)
|
2010-05-14 |
2011-11-17 |
Cornerstone Pharmaceuticals, Inc. |
Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
|
US8530444B2
(en)
*
|
2010-06-01 |
2013-09-10 |
Aposense Ltd. |
Pharmaceutical compounds
|
US9192680B2
(en)
|
2010-06-01 |
2015-11-24 |
Aposense Ltd. |
Pharmaceutical compounds
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
WO2012069972A1
(en)
|
2010-11-19 |
2012-05-31 |
Piramal Life Sciences Limited |
A pharmaceutical combination for the treatment of breast cancer
|
WO2012087943A2
(en)
|
2010-12-20 |
2012-06-28 |
The Regents Of The University Of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
TW201242597A
(en)
|
2011-03-14 |
2012-11-01 |
Piramal Life Sciences Ltd |
A synergistic pharmaceutical combination for the treatment of pancreatic cancer
|
ES2620644T3
(es)
|
2011-04-01 |
2017-06-29 |
Genentech, Inc. |
Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
|
US8962650B2
(en)
|
2011-04-18 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
EP3444363B1
(de)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
|
AU2013243873B2
(en)
|
2012-04-04 |
2016-08-25 |
Halozyme, Inc. |
Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
|
US8921419B2
(en)
|
2012-05-08 |
2014-12-30 |
Trustees Of Dartmouth College |
Triterpenoids and compositions containing the same
|
SG10201706196XA
(en)
|
2012-06-08 |
2017-08-30 |
Hoffmann La Roche |
Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
|
SI2869848T1
(sl)
|
2012-07-04 |
2017-01-31 |
F. Hoffmann-La Roche Ag |
Kovalentno vezani konjugati antigen-protitelo
|
EP2711007A1
(de)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
4-Aminopyrazolo[3,4-d]pyrimidine zur Verwendung bei der Behandlung oder Vorbeugung von primärem und metastatischem Brust- und Prostatakrebs
|
EP2711008A1
(de)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
N6,N6-dimethyladenosine zur Verwendung bei der Behandlung oder Vorbeugung von primärem und metastatischem Brustkrebs
|
EP2711009A1
(de)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
Verbindungen zur Verwendung bei der Behandlung oder Vorbeugung von primärem und metastatischem Brust- und Prostatakrebs
|
EP2919759A4
(de)
|
2012-11-14 |
2016-07-20 |
Ohio State Innovation Foundation |
Materialien und methoden zur behandlung von glioblastomen
|
MX2015004979A
(es)
|
2012-12-21 |
2015-07-17 |
Eisai R&D Man Co Ltd |
Forma amorfa de derivado de quinolina y metodo para su produccion.
|
ES2687968T3
(es)
|
2013-05-14 |
2018-10-30 |
Eisai R&D Management Co., Ltd. |
Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
|
WO2015191576A1
(en)
|
2014-06-09 |
2015-12-17 |
Lipomedix Pharmaceuticals Ltd. |
Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
|
JP6654581B2
(ja)
|
2014-06-26 |
2020-02-26 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗brdu抗体および使用方法
|
BR112017002827B1
(pt)
|
2014-08-28 |
2023-04-18 |
Eisai R&D Management Co., Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
WO2016078160A1
(zh)
*
|
2014-11-17 |
2016-05-26 |
常州方圆制药有限公司 |
胞苷衍生物及其应用
|
CN107835820B
(zh)
|
2015-01-26 |
2021-10-15 |
芝加哥大学 |
识别癌症特异性IL13Rα2的CAR T细胞
|
CN107683289B
(zh)
|
2015-01-26 |
2021-08-06 |
芝加哥大学 |
IL13Rα2结合剂和其在癌症治疗中的用途
|
MX2017010474A
(es)
|
2015-02-25 |
2017-11-28 |
Eisai R&D Man Co Ltd |
Metodo para suprimir el amargor de un derivado de quinoleina.
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
SG11201710198YA
(en)
|
2015-06-16 |
2018-01-30 |
Eisai R&D Man Co Ltd |
Anticancer agent
|
CN106317147B
(zh)
*
|
2015-07-06 |
2018-11-27 |
扬州硒瑞恩生物医药科技有限公司 |
核苷类化合物及其制备方法
|
CN109414439A
(zh)
|
2016-06-29 |
2019-03-01 |
伊莱利利公司 |
用于治疗胰腺癌的erk1/2抑制剂化合物与吉西他滨或者与吉西他滨和白蛋白结合型紫杉醇的组合
|
WO2018094406A1
(en)
|
2016-11-21 |
2018-05-24 |
Bexion Pharmaceuticals, Inc. |
A combination therapy including sapc-dops for the treatment of pancreatic cancer
|
US11034667B2
(en)
|
2017-01-09 |
2021-06-15 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
EP3664844A1
(de)
|
2017-08-07 |
2020-06-17 |
Amgen Inc. |
Behandlung von dreifach negativem brustkrebs oder kolorektalkrebs mit lebermetastasen mit einem anti-pd-l1-antikörper und einem onkolytischen virus
|
IL313238A
(en)
|
2017-09-18 |
2024-07-01 |
Univ California |
Claudin 6 antibodies and methods of cancer treatment
|
US11407723B2
(en)
|
2018-01-09 |
2022-08-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
KR20200118827A
(ko)
|
2018-02-02 |
2020-10-16 |
마베릭스 온콜로지, 잉크. |
젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
WO2020001475A1
(en)
|
2018-06-29 |
2020-01-02 |
Shanghai Changchengyiyaokeji Company Limited |
Phosphorus-containing prodrugs of gemcitabine
|
US20220031670A1
(en)
|
2018-09-20 |
2022-02-03 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations for use in the treatment of neoplastic diseases
|
WO2020144657A1
(en)
|
2019-01-11 |
2020-07-16 |
Lipomedix Pharmaceuticals Ltd. |
Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
|
CA3134055A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 antibodies and drug conjugates
|
EP3941944A4
(de)
|
2019-03-20 |
2022-11-30 |
The Regents of the University of California |
Bispezifische claudin-6-antikörper
|
AU2020266083A1
(en)
|
2019-04-30 |
2021-09-23 |
Instituto de Medicina Molecular João Lobo Antunes |
Rank pathway inhibitors in combination with CDK inhibitors
|
WO2020245198A1
(en)
|
2019-06-04 |
2020-12-10 |
Apterna Limited |
APTAMERS AGAINST TRANSFERRIN RECEPTOR (TfR)
|
JP2022538829A
(ja)
|
2019-06-24 |
2022-09-06 |
アムジェン インコーポレイテッド |
癌治療のためのSIRPγの阻害
|
CN110684062B
(zh)
*
|
2019-10-18 |
2022-12-13 |
大连大学 |
一种治疗非小细胞肺癌的药物及其制备方法
|
GB202019692D0
(en)
|
2020-12-14 |
2021-01-27 |
Apterna Ltd |
Aptamer-sirna fusions
|